NCT04971551

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

A Phase 2 ,Safety and Efficacy Study of Jaktinib Hydrochloride Tablets for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an single-arm, Phase II multi-center study. The purpose of this study is to assess the efficacy and safety of Jaktinib in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease.

Conditions

• Acute Graft-Versus-Host Disease

Interventions

Type	Name	Description
DRUG	Jaktinib Hydrochloride Tablets	Oral on an empty stomach

Timeline

• Start date: 2024-12-01
• Primary completion: 2025-06-01
• Completion: 2025-07-01
• First posted: 2021-07-21
• Last updated: 2024-03-06

Locations

1 site across 1 country: China